Two new studies demonstrating the potential of Merck’s Keytruda (pembrolizumab) as a first-line treatment for metastatic non-small cell lung cancer will be presented at the European Society for Medical Oncology (ESMO) 2016 in Denmark. The injectable drug is a humanized monoclonal antibody that amps up the body’s immune system so that it can detect and…